Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.

ABSTRACT:

Background

Little is known about the interaction of comorbidities and age on survival outcomes in colorectal cancer (mCRC), nor how comorbidities impact treatment tolerance.

Methods

We utilized a cohort of 1345 mCRC patients enrolled in CALGB/SWOG 80405, a multicenter phase III trial of fluorouracil/leucovorin + oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) plus bevacizumab, cetuximab or both. Endpoints were overall survival (OS), progression-free survival (PFS), and grade ≥ 3 toxicities assessed using NCI CTCAE v.3.0. Participants completed a questionnaire, including a modified Charlson Comorbidity Index. Adjusted Cox and logistic regression models tested associations of comorbidities and age on the endpoints.

Results

In CALGB/SWOG 80405, 1095 (81%) subjects were < 70

SUBMITTER: McCleary NJ 

PROVIDER: S-EPMC9058225 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature